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Abstract
The accumulation of poorly differentiated cells is a hallmark of breast neoplasia and progression. Thus an understanding of
the factors controlling mammary differentiation is critical to a proper understanding of breast tumourigenesis. The Inhibitor
of Differentiation 1 (Id1) protein has well documented roles in the control of mammary epithelial differentiation and
proliferation in vitro and breast cancer progression in vivo. However, it has not been determined whether Id1 expression is
sufficient for the inhibition of mammary epithelial differentiation or the promotion of neoplastic transformation in vivo.W e
now show that Id1 is not commonly expressed by the luminal mammary epithelia, as previously reported. Generation and
analysis of a transgenic mouse model of Id1 overexpression in the mammary gland reveals that Id1 is insufficient for
neoplastic progression in virgin animals or to prevent terminal differentiation of the luminal epithelia during pregnancy and
lactation. Together, these data demonstrate that there is no luminal cell-autonomous role for Id1 in mammary epithelial cell
fate determination, ductal morphogenesis and terminal differentiation.
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Introduction
In many cancers such as breast cancer, the degree of
differentiation correlates inversely with cancer grade and patient
mortality. Many canonical oncogenes and tumour suppressors
have roles in differentiation, such as Notch and Wnt [1],
Hedgehog [2], Rb [3] and BRCA1 [4].Thus an analysis of the
genes controlling mammary differentiation may lead to insights
into the factors and mechanisms controlling breast tumourigenesis.
The Id family of transcriptional regulators, composed of Id1, Id2,
Id3 and Id4 belong to the basic helix-loop-helix (bHLH) family of
transcription factors. Unlike other family members, Id proteins
lack DNA binding domains and thus act as dominant negative
inhibitors of other transcription factors, including members of the
HLH and Ets families (reviewed in [5]). By binding to these
factors, they prevent the transcription of genes typically required
for differentiation. They are expressed in complex spatiotemporal
patterns during embryonic development but their expression is
commonly downregulated in mature tissues (reviewed in [5]).
Id1 is reported to be expressed in the luminal epithelium of the
mammary gland during the early stages of mouse pregnancy [6]
and to negatively regulate terminal differentiation of luminal
epithelial cell lines in vitro [6,7,8]. However, there are no functional
data addressing whether Id1 has a role in mammary development
or differentiation in vivo. Furthermore, the validity of the antibody
typically used in immunohistochemical studies of mammary Id1
expression (Santa Cruz SC-488) is disputed and some reports
claim an absence of Id1 staining in the mammary gland [9,10].
Id1 is also reportedly upregulated in breast cancer, with high
expression correlating with poorer patient outcome [11]. Overex-
pression of Id1 promotes invasion, proliferation and migration in
vitro [12,13,14] and high Id1 expression is associated with the
metastatic phenotype of breast cancer cell lines in vivo [15]. We
have previously shown that Id1 cooperates with oncogenic Ras in
mammary tumourigenesis and metastasis in vivo [16], but the role
for Id1 overexpression alone in mammary development and
neoplasia has not been investigated.
Using a recently-developed monoclonal antibody we surveyed
the expression of Id1 in the developing mouse mammary gland.
We show that Id1 is not detected in the luminal epithelium at any
timepoint during mammary development. To address the
physiological role of Id1 in mammary development and neoplasia,
we generated a transgenic mouse overexpressing Id1 under the
control of the tetracycline regulatory element (TRE-Id1 strain). By
breeding with mice expressing the reverse tetracycline transacti-
vator (MTB strain) we generated a mouse with conditional
expression of Id1 in the mammary gland. Based on the reported
role of Id1 in preventing luminal differentiation in vitro,w e
predicted that these mice would possess dramatic defects in
terminal mammary differentiation and lactation. However, we
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e11947show that Id1 is not sufficient to prevent terminal mammary
differentiation in vivo and these mice can undergo normal pubertal
and pregnancy-associated mammary development.
Results
Expression of Id1 in the mammary gland
To determine whether Id1 is normally expressed in the luminal
epithelium during mammary development, as reported previously,
we surveyed Id1 expression using a recently described monoclonal
antibody to Id1 (Biocheck BCH-1/37-2; [9]) and compared it to
the polyclonal antibody previously used to detect Id1 (SC-488;
[6]). Staining with the polyclonal antibody was non-specific as
positive nuclear and cytoplasmic staining was observed regardless
of Id1 genotype (Figure 1A&B). The monoclonal antibody robustly
detected Id1 in the mammary gland of bi-transgenic TRE-
Id1+MTB animals as well as detecting endogenous Id1 expression
in a proportion of cells in the mammary stroma and spleen of
wildtype mice (Figure 1E). Staining of cells in the mammary
stroma and spleen was absent in tissues from knockout hosts
(Figure 1E). Staining with the monoclonal antibody BCH-1/37-2
did not readily detect Id1 expression in the mammary epithelium
at any stage of mammary development, however nuclear Id1
expression was robustly detected in immune cells, endothelial cells
Figure 1. Id1 expression in the mouse mammary gland. Santa Cruz SC-488 polyclonal antibody does not specifically recognise Id1. Mammary
glands from 10 week old virgin wildtype (A) and Id1-null (B) mice were immuno-stained for Id1 using SC-488. Note the non-specific positive staining
of epithelial cells regardless of genotype (inset). A spontaneous p53-null mammary tumor was immunostained for Id1 using SC-488 (C) or BCH-1/
#37-2 monoclonal antibody (D). (E) BCH-1/#37-2 monoclonal antibody was used to immunostain for Id1 in Id1-transgenic mammary glands, or
spleen taken from a wildtype (WT) or Id1-null mouse. Id1-positive cells in the spleen are endothelium. (F) Id1 immunostaining (BCH-1/#37-2) was
conducted on mouse mammary glands at various stages of mammary gland development: 5 weeks old, 12 week old virgin, 4 days post-coitus (dpc),
18 dpc, lactating 4 days postpartum (dpp) and lactating 15 dpp. Arrows indicate examples of Id1-positive cells.
doi:10.1371/journal.pone.0011947.g001
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readily detected in the epithelium of normal human mammary
gland derived from reduction mammoplasty (data not shown). We
next used a spontaneous mouse model of basal-like breast cancer,
derived from mammary transplants of p53 null epithelium, to test
whether Id1 could be detected in mouse mammary tumours.
Using the monoclonal antibody, Id1 positive cells were detected in
tumours at a frequency ,5–10% (Fig 1D). In comparison, the
polyclonal antibody failed to detect Id1 positive cells (Figure 1C).
These data demonstrate the high sensitivity and specificity of the
monoclonal antibody compared to the low sensitivity and
specificity of the polyclonal antibody.
Generation of an Id1-transgenic mouse
Extensive in vitro data (described earlier) suggests that Id1
controls luminal mammary epithelial cell fate and differentiation.
Id1 was previously reported to be expressed in the mammary
gland during the early stages of pregnancy, followed by a
downregulation of Id1 concomitant with an upregulation of milk
protein genes [6]. Id1 expression has also been shown to prevent
terminal differentiation and production of milk proteins by
immortalised mammary epithelial cells in culture [6,7,8,17,18].
While our earlier results suggested that Id1 is not expressed by
luminal epithelia, it is possible that our histological analysis failed
to identify a role for Id1 in luminal cell biology. Furthermore, since
Id1 is expressed by breast cancers we wanted to test whether Id1
expression can initiate hyperplastic or neoplastic change in the
mammary gland. To facilitate Id1 over-expression in the
mammary gland, mice carrying a transgene encoding a hemaglu-
tinin (HA) epitope-tagged Id1 cDNA downstream of the
tetracycline response element promoter (TRE-Id1) were generated
by pronuclear injection and crossed to mice carrying the MMTV-
rtTA transgene (MTB; [19]). Two independent lines of TRE-Id1
mice were used for subsequent analysis. Id1 transgene expression
was strongly induced in the mammary luminal epithelia of these
mice by doxycycline addition in vitro and in vivo (Figure 2). In both
transgenic lines, transgene expression was restricted to the luminal
epithelium, as determined by immunohistochemical staining
(Figure 2B, inset). There was no evidence of ‘leakiness’ in
transgene expression in the absence of doxycycline, nor was the
Figure 2. Generation of a mammary-specific conditional Id1-transgenic mouse. Mice from TRE-Id1 lines #3o r#10 were bred to MTB mice
and administered dox chow for 5 days. (A) Mammary gland extracts were western blotted for Id1. The lower band is endogenous Id1 while the upper
band corresponds to the Id1-HA transgene product. (B) Mammary glands or spleen were harvested and stained with anti-HA monoclonal antibody to
demonstrate transgene expression in the luminal, but not in the myoepithelium (arrow) or non-epithelial organs such as spleen. TRE-Id1 line #10
gave identical results.
doi:10.1371/journal.pone.0011947.g002
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presence of doxycycline (Figure 2B). Representative data for both
lines is shown in Figure 2B.
To examine the influence of Id1 expression during virgin
mammary development, mice carrying the TRE-Id1 transgene alone
or together with the MTB transgene were treated with doxycycline
from weaning at 3 weeks of age to 9 weeks of age, so that Id1 was
expressed throughout the period in which the mammary epithelium
fills the fat pad and elaborates a mature ductal tree. Mice carrying the
TRE-Myc and MTB transgenes were used as a positive control [20].
Usingcarmine-Alumstainingofmammarygland wholemountsfrom
these animals, there were no reproducible differences in ductal
morphogenesis between TRE-Id1+MTB bi-transgenics and controls
at this timepoint (Figure 3). Similarly, upon histological examination
there was no reproducible effect on mammary epithelial morphology
or stromal composition (Figure 3, Table S1). In comparison,
overexpression of the c-Myc proto-oncogene caused an increase in
ductal side-branching and hyperplastic morphology in the mammary
gland (Figure 3).
During pregnancy, the mammary gland goes through rapid
proliferation followed by entry into quiescence and terminal
differentiation (reviewed in [21]). By day 9 of pregnancy,
expression of milk proteins is induced and by day 16, WDNM1
and b-casein are widely expressed [22]. To determine whether
expression of Id1 was incompatible with terminal mammary
differentiation in vivo, Id1 expression was induced in bi-transgenic
female mice and these mice were mated to FVB/N males. At 16
days of pregnancy, mammary glands were analysed for histology
and gene expression. By whole mount (Figure 4A) and histology
(Figure 4B) TRE-Id1+MTB bi-transgenic mammary glands were
indistinguishable from those taken from similarly treated single
transgenic control mice. Activation of milk protein expression was
also unaffected, as b-casein expression was not significantly altered
between Id1 overexpressing (Double transgenic; DT) and control
glands (Single transgenic; ST; Fig 4D). To determine whether
transgenic mice overexpressing Id1 were able to produce milk and
feed pups, female bi-transgenic mice and single-transgenic controls
were given doxycycline chow at the time of mating and pups
observed. Milk was always observed in the stomach of pups from
both experimental groups, and pups derived from mothers
overexpressing Id1 grew at equivalent rates to those derived from
control mothers (Fig 4E). Together, these data demonstrate that
luminal Id1 expression does not control pubertal and pregnancy-
associated mammary development nor prevent terminal differen-
tiation of mammary epithelia.
Discussion
Based on correlative analysis of Id1 expression during mammary
developmentand experimentationwithcelllines[6,7,8], Id1 hasbeen
proposed to regulate mammary differentiation and cell fate decisions.
Using a highly sensitive and specific antibody we now provide
definitive evidence that Id1 is not abundantly expressed in the
mammary epithelium. Previous studies have reported Id1 expression
in the mammary gland based on immuno-staining with a polyclonal
antibody or by northern blotting of whole mammary extracts. We
show that the polyclonal antibody has poor sensitivity and low
specificity, and returns strongly positive immunostaining in both
wildtype and Id1-null mammary glands. We detect Id1 expression in
a number of stromal cell types, thus northern blotting of mammary
extracts most likely detects Id1 expression in stromal cells rather than
in the epithelium. However, Id1 may be expressed in rare epithelial
Figure 3. Ectopic Id1 expression is not sufficient to perturb virgin mammary gland development. Mice from TRE-Id1 lines #3 and #10
or TRE-Myc were bred to MTB mice and administered dox chow from 3 to 10 weeks of age to induce transgene expression. Mammary morphogenesis
was analysed by carmine alum whole mounts (above) and by hematoxylin and eosin staining of sections from formalin-fixed, paraffin embedded
glands (below). The histology of Id1 transgenic glands was unaffected by Id1 transgene expression during virgin mammary development, while
control myc-transgenic glands display a hyperplastic phenotype. Images are representative of at least 5 mice per group, across two independent
transgenic lines.
doi:10.1371/journal.pone.0011947.g003
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this possibility.
Id1 expression has previously been reported to correlate with poor
prognosis in breast cancer [11], however that study used the
polyclonal antibody that we report here to be non-specific and
insensitive in mouse tissues. While we did not readily detect Id1 in the
normal mammary epithelium, we did detect Id1 expression in a
mouse mammary cancer model, and have similarly detected Id1 in
human breast cancer cell lines and clinical cases (AS, unpublished
data). This suggests that Id1 expression is activated during mammary
neoplasia and that the prognostic significance of Id1 expression in
breast cancer cohorts should be re-evaluated using this new
monoclonal antibody, which we are currently pursuing.
Based on previous reports, we predicted that overexpression of
Id1 in the luminal epithelial cells of the mammary gland would
dramatically alter mammary development and pregnancy-related
maturation. However, we demonstrate that Id1 expression alone is
not sufficient to alter luminal epithelial cell fate nor to prevent
terminal differentiation. Id1 transgenic mice underwent normal
pubertal and pregnant mammary gland development, and were
able to lactate and feed pups as normal. These data raise the
question of why Id1 failed to regulate differentiation or mammary
development. Unlike cells from control mice, cells taken from
TRE-Id1 + MTB bi-transgenic mice were fully transformed by
transduction with oncogenic h-Ras
V12 expression (Figure S1) as
previously reported [16], demonstrating that the Id1 transgene is
active in these cells. The failure to regulate mammary develop-
ment may therefore be a result of expression of the transgene in a
non-physiologically relevant cell type, as we do not currently know
whether the MMTV promoter directs transgene expression in the
appropriate cell type in which Id1 is physiologically expressed.
These results are consistent with a recent report that failed to
detect a histological phenotype following Id1 transgene overex-
pression in the prostatic epithelium [23].
Materials and Methods
Generation and handling of mice
To determine the role for Id1 in mammary development and
neoplasia in vivo, we generated a mouse carrying a transgene
encoding murine Id1 cDNA under the control of the modified
tetracycline response element, TREtight (Clontech). Linearised
DNA encoding the transgene was injected into the pronuclei of
FVB/N fertilized mouse oocytes by the UCSF transgenic core
facility. Transgenic offspring were bred to FVB/N to establish two
independent founder lines, named Id1#3 and Id1#10. Integra-
tion of the transgene was validated by southern blotting (data not
shown) and expression was validated by harvesting tail fibroblasts,
infecting with a retroviral construct encoding the tetracycline
transactivator (tTA) and western blotting for Id1 (data not shown).
MMTV-rtTA ([19];MTB) and TRE-Myc [24] mice were kindly
provided by Dr Lou Chodosh (University of Pennsylvania). Mice
were administered doxycycline by chow ad libitum (Bioserv Inc
;200 mg/kg). Experimental mice were treated according to
protocol # 07/41 approved by the Institutional Animal Ethics
Committee of the St Vincent’s Hospital (Sydney) campus.
Analysis of mammary gland and tumour specimens
For analysis of the effects of Id1 on pregnancy-induced
mammary development, Id1 expression was induced in female
nulliparous mice from ,8 weeks of age, then at 10–12 weeks of
age these mice were mated to FVB/N males and checked for plugs
daily. After 16 days of pregnancy, mammary glands were collected
and RNA was collected or glands were fixed and embedded into
paraffin blocks.
RNA was prepared by Trizol (Invitrogen) extraction, followed by
RT-PCR analysis for Id1, keratin 8 and b-casein using Taqman pre-
designed gene expression assays (Applied Biosystems).
Mammaryglandsandmousemammarytumourswerefixedin4%
paraformaldehyde for 4–24 hours then transferred to 70% ethanol
prior to processing and embedding in paraffin blocks. 4 mMs e c t i o n s
were cut and stained either with hemotoxylin and eosin (H&E) or
with antibodies to Id1 (Santa Cruz SC-488 or Biocheck clone BCH-
1/37-2), HA (Santa Cruz SC-488), Cytokeratin 14 (Covance) using
standard procedures. Whole mounts of transgenic mammary glands
were also stained with Carmine Alum using a standard protocol.
Histological analysis of mouse mammary glands was performed by a
pathologists specialising in comparative pathology (ADB) blinded to
the identity of each sample.
Supporting Information
Figure S1 Mammary epithelial cells from TRE-Id1 X MTB
transgenic mice are fully transformed by Ras activation. Epithelial
cells from TRE-Id1 (line #3) X MMTV-rtTA mice were infected
with a retrovirus encoding activated Ras, transplanted to the fat
pad of four recipient mice and observed for 50 days. Aggressive
tumours formed in all mice receiving these cells, and tumour
diameters are shown. Wild-type epithelial cells transduced with
Ras failed to form tumours. Preparation, infection and transplan-
tation of cells was performed as previously described [16].
Found at: doi:10.1371/journal.pone.0011947.s001 (5.00 MB TIF)
Table S1 Tabulation of histological analysis. Quantitation of
histological analysis of 16 control (TRE-Id1 single transgenic +
Dox) or 12 Id1-overexpressing mammary glands (TRE-Id1 X
MMTV-rtTA + Dox) as described for Figure 3. A specialist
veterinary pathologist (ADB) scored these as either (i) ‘normal-like’
or showing evidence of increase (ii) lobulogenesis or proliferation,
(iii) ductal branching or (iv) a stromal reaction. The distribution of
these phenotypes is similar between control and Id1 transgenic
mice. Data from TRE-Id1 lines #3 and #10 have been
combined.
Found at: doi:10.1371/journal.pone.0011947.s002 (0.06 MB
XLS)
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Figure 4. Id1 does not control terminal differentiation in the mammary gland. TRE-Id1/MTB double transgenic (DT) females or single
transgenic (ST) controls were placed on dox chow from 6 weeks. (A–D) At ,8–20 weeks, females were mated to wildtype males. At 16 days post
coitus, mammary glands were harvested and analysed by carmine whole mount (A), sectioned for histology (B) or RNA extracted and analysed for Id1
(C) and b-casein gene expression (D). To determine whether TRE-Id1/MTB bitransgenic mice can lactate, pups were weighed after birth for up to 8
days and the average weight per litter compared to or single transgenic control mice (E).
doi:10.1371/journal.pone.0011947.g004
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